Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy

Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Any of the following prior therapies:

* Chemotherapy =\< 21 days prior to registration

* Mitomycin C/nitrosoureas =\< 42 days prior to registration

* Immunotherapy =\< 14 days prior to registration

* Biologic therapy =\< 14 days prior to registration

* Prior investigational therapy =\< 28 days prior to registration

* Full field radiation therapy =\< 28 days prior to registration or limited field radiation therapy \< 14 days prior to registration

* Full field radiation encompasses the entire area of known disease involvement and surrounding uninvolved but at-risk areas, e.g. subtotal nodal (mantle and upper abdomen) or total nodal irradiation

* Limited field radiation is restricted to treating only the known areas of clinical disease, e.g. involved-field therapy for lymphoma

* Major surgery (i.e., laparotomy) =\< 4 weeks prior to registration; minor surgery =\< 2 weeks prior to registration; Note: insertion of a vascular access device is not considered major or minor surgery in this regard

Unresolved toxicities from prior therapy with the exception of alopecia that have not resolved to =\< grade 1, unless the patient has a chronic, stable =\< grade 2 toxicity that would not interfere with the evaluation of the study agents

New York Heart Association classification III or IV

Central nervous system (CNS) metastases or seizure disorder; Note: CNS metastases are allowed if previously treated and stable for at least 4 weeks

Any of the following:

* Pregnant women

* Nursing women

* Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, injections, intrauterine device \[IUD\], or abstinence, etc.); oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study

Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration \[FDA\]-approved indication and in the context of a research investigation)

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive on highly active antiretroviral therapy (HAART) therapy

Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm

Other active malignancy =\< 3 years prior to registration; EXCEPTIONS: nonmelanotic skin cancer or carcinoma-in-situ of the cervix; Note: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer

History of myocardial infarction =\< 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

Uncontrolled hypertension, labile hypertension of history of poor compliance with antihypertensive medication

Patients with active, bleeding diathesis

Non-disease related- major surgery, =\< 28 days or minor surgery =\< 7 days prior to registration

What this study is about